Bicyclic heterocycle derivatives and methods of use thereof

A compound having the formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• A is —O—, —S—, —NH—, or —N(C1-C6alkyl)-;
• B is:
• J is —C(R11)— or —N—;
• M is —C(R11)— or —N—;
• W is a bond, C1-C6alkyl, —C(O)—, —C(O)—O—, —S(O)2—, —S(O)2—N(R10)—, C(S)O or —C(O)—N(R10)—;
• X is —O—, —S—, —NH, —N(C1-C6alkyl), —N(cycloalkyl), —N(hydroxyalkyl) or —N(hydroxyaryl);
• Z is a bond, —C(O)—, —C═NOR12, —C═C(R14)2, —C(R1)2—, —O—, —N(R10)— or —S(O)n—;
• each occurrence of R1 is independently hydrogen, C1-C6alkyl, cycloalkyl, halogen, haloalkyl or —OR7, wherein OR7 is not adjacent to —N—W—R3;
• each occurrence of R2 is independently hydrogen or C1-C6alkyl;
• R3 is C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, haloalkyl, —(C1-C6alkyl)t-cycloalkyl, —(C1-C6alkyl)t-heterocycloalkyl, —(C1-C6alkyl)t-aryl or —(C1-C6alkyl)t-heteroaryl, wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl group can be unsubstituted or substituted with one or more substituents each independently selected from R9;
• each occurrence of R4 is independently hydrogen or C1-C6alkyl;
• each occurrence of R7 is independently hydrogen or C1-C6alkyl;
• Ar is aryl, heteroaryl, heterocycloalkyl or cycloalkyl, any of which can be unsubstituted or substituted with one or more substituents each independently selected from R9;
• R8 is hydrogen, halogen, C1-C6alkyl or cycloalkyl;
• R9 represents C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, halogen, haloalkyl, —CN, —NO2, —O—(C1-C6alkyl)t-R13, —S—(C1-C6alkyl)t-R13, —N(R13)—(C1-C6alkyl)t-R13, —(C1-C6alkyl)t-R13, —C(O)—(C1-C6alkyl)t-R13, —C(O)O—(C1-C6alkyl)t-R13, —N(R7)C(O)—(C1-C6alkyl)t-R13, —C(O)N(R7)—(C1-C6alkyl)t-R13, —OC(O)—(C1-C6alkyl)t-R13, —N(R7)C(O)N(R7)—(C1-Colkyl)t-R13, —N(R7)C(O)O—(C1-C6alkyl)t-R13, —S(O)—(C1-C6alkyl)t-R13 or —S(O)2(C1-C6alkyl)t-R13;
• R10 is hydrogen, C1-C6alkyl, aryl, or —C(O)OR4;
• each occurrence of R11 is independently hydrogen, C1-C6alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, —N(R7)2 or halogen;
• each occurrence of R12 is independently hydrogen, C1-C6alkyl or aryl;
• each occurrence of R13 is independently hydrogen, hydroxyl, haloalkyl, aryl, cycloalkyl, —COOC1-C6alkyl, —OC1-C6alkyl or heteroaryl;
• each occurrence of R14 is independently hydrogen, C1-C6alkyl or aryl, or both R14 groups, and the carbon atom to which they are attached, combine to form a cycloalkyl or heterocycloalkyl group;
• each occurrence of n, p, q, r, s, t and u is independently 0, 1 or 2.

A compound of formula Ib

• or pharmaceutically acceptable salt thereof, wherein:
• W is a bond, C1-C6alkyl, —C(O)—, —C(O)O—, —C(S)O— or —SO2;
• X is —O—, —S—, —NH or —N(C1-C6alkyl);
• R3 is C1-C6alkyl, cycloalkyl, haloalkyl or heteroaryl, wherein cycloalkyl is unsubstituted or substituted with 1 to 3 substituents each independently selected from the group consisting of C1-C6alkyl, halogen, OC1-C6alkyl, and CO(O)C1-C6alkyl, wherein the heteroaryl is unsubstituted or substituted with 1 to 3 substituents each independently selected from the group consisting of C1-C6alkyl, cycloalkyl, haloalkyl, halogen, —CN and OC1-C6alkyl, and wherein the haloalkyl is unsubstituted or substituted with 1 to 3 substituents each independently selected from the group consisting of haloalkyl;
• R15 is C1-C6alkyl, cycloalkyl, haloalkyl, halogen, —O—C1-C6alkyl, —CN, —COC1-C6alkyl, —C1-C6alkyl-OH, —C(O)O—C1-C6alkyl, —CO-cycloalkyl, —S(O)2C1-C6alkyl, —S(O)2cycloalkyl, or heteroaryl
• R16 is halogen;
• and
• R17 is hydrogen or halogen.